Carvolix Reports Successful Postmarketing Results for TAVIPILOT AI Software

May 04, 2026
Carvolix announced positive results from its SAITO clinical program evaluating the TAVIPILOT AI software for Transcatheter Aortic Valve Implantation procedures, achieving full procedural success across studies in France and Australia.

Carvolix announced the completion of its SAITO postmarketing clinical program evaluating the TAVIPILOT software used during Transcatheter Aortic Valve Implantation procedures. The program included three studies involving 30 patients across France and Australia.

The company reported a 100 percent procedural success rate and high clinician satisfaction with the software. TAVIPILOT assists medical teams in precise positioning of heart valves during implantation and has received clearance for commercial use in the United States.

The positive results from the SAITO program support broader clinical adoption of TAVIPILOT as a guidance tool for valve placement. Carvolix also published its 2025 Universal Registration Document and confirmed an extension of its cash runway through additional funding.

We hope you enjoyed this article.

Consider subscribing to one of our newsletters like Life AI Weekly or Daily AI Brief.

Also, consider following us on social media:

Subscribe to Life AI Weekly

Weekly coverage of AI applications in healthcare, drug development, biotechnology research, and genomics breakthroughs.

Market report

2025 Generative AI in Professional Services Report

Thomson Reuters

This report by Thomson Reuters explores the integration and impact of generative AI technologies, such as ChatGPT and Microsoft Copilot, within the professional services sector. It highlights the growing adoption of GenAI tools across industries like legal, tax, accounting, and government, and discusses the challenges and opportunities these technologies present. The report also examines professionals' perceptions of GenAI and the need for strategic integration to maximize its value.

Read more